APRE Profile
Aprea Therapeutics, Inc., a biopharmaceutical company, is dedicated to the development and commercialization of synthetic lethality-based cancer therapeutics, specifically targeting critical pathways and central targets involved in DNA damage response and cancer progression. The company’s innovative approach leverages synthetic lethality to selectively target cancer cells, aiming to enhance treatment efficacy while minimizing adverse effects. Aprea’s cutting-edge research focuses on identifying and exploiting vulnerabilities in cancer cells, positioning it at the forefront of next-generation cancer therapies.
The cornerstone of Aprea Therapeutics' pipeline is ATRN-119, a clinical-stage small molecule ATR inhibitor. ATRN-119 is being developed for the treatment of solid tumors, with the potential to address significant unmet medical needs in oncology. By inhibiting ATR, a protein kinase involved in the DNA damage response, ATRN-119 aims to induce synthetic lethality in cancer cells deficient in certain DNA repair mechanisms, thereby selectively targeting tumor cells while sparing normal tissues. The promising preclinical and early clinical data underscore the therapeutic potential of ATRN-119 in a variety of solid tumor indications.
Headquartered in Doylestown, Pennsylvania, Aprea Therapeutics operates with a robust scientific and clinical development framework. The company is committed to advancing its pipeline through rigorous research, strategic collaborations, and a patient-centric approach. Aprea's experienced management team brings a wealth of expertise in oncology drug development, regulatory affairs, and commercialization, which is instrumental in driving its mission to transform cancer treatment paradigms.
Beyond ATRN-119, Aprea Therapeutics is actively expanding its pipeline with additional programs targeting other critical components of the DNA damage response and synthetic lethality pathways. The company’s research endeavors are supported by a strong intellectual property portfolio and collaborations with leading academic and research institutions. By harnessing the power of synthetic lethality and focusing on precision oncology, Aprea Therapeutics aims to develop innovative therapies that significantly improve outcomes for cancer patients worldwide.
|
